A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

The primary objective of this proof of mechanism pilot clinical trial is to determine if the RXR agonist bexarotene acts in humans to alter the CSF levels of apoE and alter the clearance of Amyloid-Beta

Key facts

Study ID

NCT02061878

Run by

ReXceptor, Inc.

People needed

12

Starts

2014-08-01

Expected to finish

2014-11-01

Last updated by the study team

2015-08-13

Who can join

Age: 21 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Young healthy adults (age 21-50)
• APOE3/3 genotype

You may not qualify if…

• Contraindications for blood or CSF sampling
• Bleeding disorder or taking anticoagulants/antiplatelets
• Chronic active infection
• Blood donation within the past month
• Active drug/alcohol dependence or abuse history with in the last 12 months
• Thyroid dysfunction
• High triglycerides (>3.5 mmol/L)
• High cholesterol (>4.0 mmoL/L)
• Leukopenia, including low neutrophil count (<3 x 10\^9/L)
• Neurological or psychiatric disorders
• Homeless or prisoner
• Pregnancy
• Incapable of self-informed consent
• Blood borne disease (HIV, Hepatitis)
• Actively smoking and incapable of using nicotine patches
• Known drug allergy to pain medication or local anesthetic
• Subjects that have participated in another study in the last 30 days
• Abnormalities in lumbar spine previously known within 12 months
• APOE2 or APOE4 allele
• Abnormal EKG

Where it is running

• Compass Research — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.